Predicting Recurrence-Free Survival After Upfront Surgery in Resectable Pancreatic Ductal Adenocarcinoma: A Preoperative Risk Score Based on CA 19-9, CT, and <sup>18</sup>F-FDG PET/CT-Reference-Cited by-同舟云学术

Predicting Recurrence-Free Survival After Upfront Surgery in Resectable Pancreatic Ductal Adenocarcinoma: A Preoperative Risk Score Based on CA 19-9, CT, and ¹⁸F-FDG PET/CT

Published:2024 Issue:7 Volume:25 Page:644
ISSN:1229-6929
Container-title:Korean Journal of Radiology
language:en
Short-container-title:Korean J Radiol

Author:

Jeong Boryeong¹^ORCID,Oh Minyoung²^ORCID,Lee Seung Soo¹^ORCID,Kim Nayoung³^ORCID,Kim Jae Seung²^ORCID,Lee Woohyung⁴^ORCID,Kim Song Cheol⁴^ORCID,Kim Hyoung Jung¹^ORCID,Kim Jin Hee¹^ORCID,Byun Jae Ho¹^ORCID

Affiliation:

1. Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

2. Department of Nuclear Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

3. Department of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

4. Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

Funder

National Research Foundation of Korea

Publisher

XMLink

Link

https://kjronline.org/pdf/10.3348/kjr.2023.1235

Reference38 articles.

1. Pancreatic cancer

2. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score

3. National Comprehensive Cancer Network. Pancreatic adenocarcinoma, version 2.2022. NCCN clinical practice guidelines in oncology. accessed on June 10, 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf

4. Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches

5. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial